Bari

• Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended recruitment
  2023-509408-13-00 6 2022-09-20 Solid tumors
• Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF … Ended recruitment
  2023-507964-38-00 5 2022-09-01 Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended recruitment
  2023-507933-12-00 5 2022-08-18 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory … Ended recruitment
  2024-513295-18-00 4 2022-08-10 Relapsed or Refractory Peripheral T-cell Lymphomas
• Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study Ended recruitment
  2024-516604-41-00 4 2022-08-08 Non-small Cell Lung Cancer
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended recruitment
  2023-510019-20-00 5 2022-07-13 Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis
• A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maint … Ended recruitment
  2024-516157-41-00 4 2022-05-27 Metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce … Ended recruitment
  2023-509943-28-00 5 2022-05-18 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
• A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended recruitment
  2023-507131-38-00 5 2022-05-16 Neovascular Age-Related Macular Degeneration (nAMD)
• Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Ended recruitment
  2024-517424-18-00 6 2022-05-10 Patients with EGFR mutant NSCLC according to TP53 mutational status
• A study in patients with skin cancer Ended recruitment
  2024-516914-39-00 5 2022-04-27 Metastatic or unresectable melanoma
• A study to evaluate KER-050 as a monotherapy or in combination with Ruxolitinib in Myelofibrosis. Ended recruitment
  2023-507468-38-00 4 2022-04-22 Myelofibrosis
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc … Ended recruitment
  2023-510097-14-00 5 2022-04-15 Patients with MMR deficient relapse or advanced / metastatic endometri
• Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended recruitment
  2023-504597-37-00 5 2022-03-25 Focal segmental glomerulosclerosis
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended recruitment
  2023-506771-10-00 5 2022-03-11 Breast Neoplasm, Neoplasm Metastasis
• Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi … Ended recruitment
  2023-510432-36-00 4 2022-03-01 Acute Myeloid Leukemia with NPM1 mutation
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu … Ended recruitment
  2023-506516-40-00 5 2022-02-11 Relapsing-Remitting Multiple Sclerosis
• Study aimed at evaluating the efficacy of a combination treatment (decitabine and venetoclax) in patients with Acute Myeliode Leukemia who a … Ended recruitment
  2023-510241-16-00 4 2021-12-03 Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph … Ended recruitment
  2024-511636-27-00 5 2021-12-01 Follicular Lymphoma
• A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance … Ended recruitment
  2023-509133-39-00 5 2021-11-29 Hormone receptor positive, HER2-negative advanced breast cancer
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati … Ended recruitment
  2023-507342-84-00 5 2021-10-26 Bladder Cancer
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended recruitment
  2022-503105-38-00 5 2021-10-22 MET-driven, unresectable and locally advanced or metastatic Papillary

Showing 241–264 of 368 trials